Immuron FY26 Sales Update

• FY26 sales up 6% globally
• Australia sales up 10%
• USA sales up 7% in AUD, 13% in USD
• Canada sales down 55% in FY26
• New marketing initiatives driving growth

Immuron Limited, an Australian biopharmaceutical company, announced continued sales growth for its product Travelan®, an over-the-counter immune supplement targeting pathogenic bacteria. Global FY26 sales increased by 6% to AUD$7.7 million, with Australia seeing a 10% increase to AUD$5.8 million. In the USA, sales rose 7% in AUD to AUD$1.8 million and 13% in USD to USD$1.2 million. Conversely, Canadian sales dropped 55% to AUD$0.2 million. Growth was driven by marketing initiatives and increased brand awareness. The company also highlighted its platform technology for developing medicines targeting infectious diseases.

FY26 sales up 6% globally, Australia up 10%, USA up 7% in AUD, 13% in USD, Canada down 55%

Immuron anticipates continued growth driven by marketing initiatives and increased brand awareness, with a focus on expanding its product portfolio.